AI control tightens as cures keep advancing
The system is still expanding on both fronts: 21,174 active cure-related trials are now running while 20 new wire signals and 11 new cure research items landed in the last 24 hours. On the AI side, the day’s pattern is consolidation and control — NVIDIA is pushing deeper into the AI factory stack, Anthropic has halted access to Fable 5 and Mythos 5 under a U.S. directive, and Scale AI has named a new CEO. In medicine, the signal is quieter but real: the European Commission approved Jascayd for IPF and PPF, and the FDA approved Leqembi IQLIK for early Alzheimer’s initiation dosing. The pace is uneven, but the direction is not ambiguous: infrastructure is tightening while therapeutic access keeps broadening. The window is still open.
New infrastructure and control moves dominated the AI wire, while cure-related developments included EU approval of Jascayd and FDA approval of Leqembi IQLIK.
Consolidation in AI infrastructure and model access shapes who controls the computational layer accelerating science, while each new approval expands real-world options for patients facing fatal or progressive disease.
Watch whether the AI stack keeps centralizing around a small number of platforms and whether additional approvals convert this week’s regulatory momentum into broader patient access.